Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Slides:

Advertisements

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Advertisements

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 3. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures. Ultrasound-mediated BMP-6 gene delivery to mini-pig tibial bone fractures.

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.

BET inhibition and depletion repress the expression of BRCA1 and RAD51

Fig. 2. Bestatin treatment improves tail anatomy and restores lymphatic function. Bestatin treatment improves tail anatomy and restores lymphatic function.

Fig. 4. Bexarotene promotes PPARδ activation of target genes in mouse brain and muscle. Bexarotene promotes PPARδ activation of target genes in mouse brain.

Effects of highly concentrated SFN provided as BSE in T2D patients

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 2. dAST using dPCR is robust to the presence of high concentrations of commensal bacteria due to the specificity of NA amplification. dAST using dPCR.

Fig. 4. Biomechanical properties of treated tibiae.

JQ1 directly represses the promoter activities of BRCA1 and RAD51

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Fig. 1. Bacterial communities shift during AD disease progression.

Fig. 3. A circadian rhythm in fibroblast wound-healing response.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 2. GPC3 expression in normal and tumor tissues.

Bio-AMS enhances the activity of rifampicin and ethambutol in vitro

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Increased ADMA in pregnancy is associated with SGA birth outcomes

STDP regulates synchrony in fusiform cells of the guinea pig DCN

Fig. 1 Chemical inactivation of BPL kills Mtb and prevents growth in mouse macrophages. Chemical inactivation of BPL kills Mtb and prevents growth in mouse.

Fig. 4. Geographic atrophy progression in CFI risk-allele carriers and risk-negative subpopulations after monthly lampalizumab treatment. Geographic atrophy.

Fig. 4 CXCL4 potentiates TLR8-mediated activation of SSc pDCs.

Fig. 5. Remnants of PS+ platelets induce neutrophil macroaggregation.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 5. In vivo characterization of adipogenesis by CT.

Fig. 6. A circadian rhythm in keratinocyte wound healing and a diurnal variation in human burn healing outcome. A circadian rhythm in keratinocyte wound.

Fig. 1. MAHALO clinical trial flowchart.

Fig. 4. MATE1 transcription in RCC.

Fig. 6. Safety assessment in cynomolgus monkey.

Fig. 4 Nanocages captured multiple TB-related analytes.

Fig. 5. MMP-7 expression in human liver, EHBD, and gallbladder.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 4. Actin polymerization rhythms are required for circadian regulation of adhesion and wound-healing efficacy by fibroblasts. Actin polymerization.

Fig. 3. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation. Recovery of AVP-deficient rats from anemia induced by sublethal irradiation.

Fig. 2. Pathways differentially regulated in patients with early Lyme disease and STARI. Pathways differentially regulated in patients with early Lyme.

Fig. 3. The effects of DCA on hemodynamic and functional end points and their association with genetic factors (variants of the SIRT3 and UCP2 genes) that.

Fig. 1. Map showing the study catchment area in the East of England.

Fig. 4. Analysis of T cell responses according to treatment and in peptide-treated C-peptide responders and nonresponders. Analysis of T cell responses.

Fig. 5 CXCL4 potentiates TLR9-mediated activation but has minimal effect on TLR7-mediated activation of pDCs purified from SSc or HDs. CXCL4 potentiates.

Fig. 4. Irisin protected against oxidative stress and apoptosis in IR-injured lung tissue. Irisin protected against oxidative stress and apoptosis in IR-injured.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Fig. 2 Analysis of CLL lymph nodes.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 6. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections. Analysis of SHIV-325c V1V2 envelope sequences in breakthrough infections.

Human HFpEF is associated with impaired cardiac myofibril relaxation

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 4. Acute lung injury in miR-223−/y mice.

Fig. 3 CSF1 is expressed in human melanoma.

Decreased weight and adiposity is transmissible via the gut microbiota

Fig. 7 Vaccine-induced influenza-specific B cells are not maintained in peripheral blood. Vaccine-induced influenza-specific B cells are not maintained.

IIV induces CD21hiCD27+ and CD21loCD27+ influenza-specific B cells

Fig. 3 Activation of freshly isolated CD4+ T cells from HIV-infected patients on ART selectively reverses baseline blocks to splicing, elongation, and.

Fig. 5 Early and modest immune response at day 3 after exposure in Delayed animals. Early and modest immune response at day 3 after exposure in Delayed.

Fig. 4 cTFH1 cells correlate with a boosting of influenza-specific memory B cells. cTFH1 cells correlate with a boosting of influenza-specific memory B.

Fig. 5 Wireless, full-body pressure mapping on a human subject in a hospital bed. Wireless, full-body pressure mapping on a human subject in a hospital.

Fig. 2. BET inhibition enhances PARPi-induced DNA damage.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Auditory-somatosensory bimodal stimulation desynchronizes brain circuitry to reduce tinnitus in guinea pigs and humans by Kendra L. Marks, David T. Martel,

Line graph showing mean (SEM) values for ankle pain on activity for intermittent and standard groups at baseline and week 1, 2, 3, 4, and 6 after injury.

Fig. 3. Association between peak CTL019 expansion and response.

Presentation transcript:

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. (A) Mean loudness by group. Group 1 (n = 10) received the active treatment first; group 2 (n = 10) received the sham treatment first. Loudness was assessed using the interactive software TinnTester, in which subjects match their tinnitus loudness and spectrum to an externally presented sound (see Materials and Methods). (B) Mean changes (normalized to baseline) in loudness matching for each condition. (C) Mean TFI changes (relative to baseline) for groups 1 and 2. (D) Mean changes (relative to baseline) in TFI scores. Error bars are SEM. dB SPL, decibels sound pressure level. Kendra L. Marks et al., Sci Transl Med 2018;10:eaal3175 Published by AAAS